Share Name Share Symbol Market Type Share ISIN Share Description
GlaxoSmithKline LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +7.00p +0.46% 1,524.00p 1,524.00p 1,524.50p 1,527.00p 1,516.00p 1,516.00p 1,619,729 11:20:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27,889.0 1,939.0 18.8 81.1 74,834.40

GlaxoSmithKline (GSK) Latest News (1)

More GlaxoSmithKline News
GlaxoSmithKline Takeover Rumours

GlaxoSmithKline (GSK) Share Charts

1 Year GlaxoSmithKline Chart

1 Year GlaxoSmithKline Chart

1 Month GlaxoSmithKline Chart

1 Month GlaxoSmithKline Chart

Intraday GlaxoSmithKline Chart

Intraday GlaxoSmithKline Chart

GlaxoSmithKline (GSK) Discussions and Chat

GlaxoSmithKline (GSK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
10:20:001,524.001121,706.88AT
10:20:001,524.005007,620.00AT
10:20:001,524.002804,267.20AT
10:20:001,524.003204,876.80AT
10:20:001,524.006009,144.00AT
View all GlaxoSmithKline trades in real-time

GlaxoSmithKline (GSK) Top Chat Posts

DateSubject
24/8/2017
09:20
GlaxoSmithKline Daily Update: GlaxoSmithKline is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GSK. The last closing price for GlaxoSmithKline was 1,517p.
GlaxoSmithKline has a 4 week average price of 1,464.50p and a 12 week average price of 1,464.50p.
The 1 year high share price is 1,735.50p while the 1 year low share price is currently 1,447.50p.
There are currently 4,910,393,922 shares in issue and the average daily traded volume is 7,209,464 shares. The market capitalisation of GlaxoSmithKline is £74,736,195,492.84.
17/8/2017
13:25
garycook: Hikma Pharmaceuticals plc’s pain could be GlaxoSmithKline plc’s gain Zach Coffell | Thursday, 17th August, 2017 | More on: GSK HIK Hikma Pharmaceuticals (LSE: HIK) today downgraded its 2017 forecast for the third time this year and now expects revenues of around $2bn, down from previous guidance of $2.1bn-$2.2bn. The announcement of a licensing agreement with Takeda couldn’t prevent the shares from plummeting 9% in early trading, knocking the share price down to nearly half what it was just 12 months ago. The company was hit by the devaluation of the Egyptian pound and an increasingly tough environment in the US where “competition is increasing and pricing pressure is intensifying,” according to CEO Said Darwazah. First-half revenue rose 1%, while operating profit fell 7% after a strong performance in Generics was offset by a weaker showing from Branded Generics. Strong operating cash flow helped the company reduce net debt from $697m to $633m, a perfectly healthy level considering the defensive nature of pharma companies. Investors will surely be disappointed, but some cautiously optimistic comments regarding Hikma’s Advair generic will go some way to soothing long-term fears. Sales of Advair, GlaxoSmithKline̵7;s (LSE: GSK) premier blockbuster drug, have held up better than expected since its patent expired back in 2016, because the Diskus delivery system it employs has been a tough one to crack for both Hikma and rivals Mylan and Novartis alike. Hikma said it has managed to “clarify and resolve” a number of the FDA’s questions regarding the key drug and reiterated there were “no material issues” concerning eventual approval. A more detailed update has been promised, but given the deterioration in the company’s outlook, investors might not relax until more context has been given. These delays are certainly to the benefit of Glaxo. Its massive 5.3% yield is barely covered by cash-flow and the extended no-competition period for Advair grants some much-needed breathing space so it can squeeze more out of its other businesses. Right direction I firmly believe that GSK is moving in the right direction and that a combination of margin expansion and slow-but-steady sales growth will eventually better cover the dividend. If this happens, it would not be surprising to see the shares re-rate to a more normal yield of around 4.5%, indicating a near 20% upside if the market gets comfortable with the payout. The company’s free cash flow jumped from £0.1bn in the first half of this year to £0.4bn, but if it is to achieve its target “to build free cash flow cover of the annual dividend to a target range of 1.25-1.50x,” it must continue its run of form. The rate of inevitable decline in Advair sales will be key for GSK over the next few years, as will performance in its HIV division which has really picked up the slack for the company of late. The firm did warn of “the impact of generic competition to Epzicom/Kivexa,̶1; so investors would do well to keep a close eye of the performance from the HIV treatments in future updates. I find both companies attractive propositions at current prices. Hikma has had a terrible year, but its strong presence in North Africa and the Middle East should continue to drive growth as healthcare spend increases. Similarly, Glaxo might run into some short-term issues covering the dividend, but its pipeline looks bright and I’m cheered by new CEO Emma Wamlsley’s strategic plan, specifically regarding a refocusing of capital allocation in the pharma business.
28/7/2017
14:19
zho: Emma Walmsley seeks long-term health for GSK All chief executives of GlaxoSmithKline, it seems, start their reigns by declaring they are on a mission to improve productivity in the pharmaceutical labs. Sir Andrew Witty created “discovery performance units” to get the scientists to work more efficiently. Now Emma Walmsley, his successor, is dishing out stiffer prescriptions. She is cutting 30 development programmes and declaring that 80% of the capital will be allocated to just four “priority” therapy areas, including respiratory and HIV/infectious diseases, where GSK is already big. The new policy makes sense. Drug companies must spread themselves thinly when they are pursuing original discoveries because they don’t know what they will find. But in the development stage, which is when the bills become huge, they cannot bet on everything. If you’re spending $4.5bn (£3.5bn) a year on R&D, taking a hard-headed commercial view of the best prospects sounds entirely fair. Investors sounded bored, however. The share price fell 2.5%, which wasn’t solely caused by GSK’s slight trim to earnings estimates after choosing to accelerate the launch of an important HIV drug. Maybe a long-term story of self-improvement was bound to sound dull but, whatever the reason, Walmsley should not be deterred. She has committed to GSK’s current corporate structure, which houses complex pharmaceuticals, vaccines and consumer products under one roof. After generic competition for asthma drug Advair arrives (probably next year), GSK’s next big patent cliff isn’t until 2026. The same-again dividend is virtually guaranteed for this year and next. She can afford to take a long-term approach. https://www.theguardian.com/business/nils-pratley-on-finance/2017/jul/26/itvs-buoyant-share-price-suggests-love-island-isnt-a-blip-on-the-chart
01/7/2017
08:26
tradermichael: m_k_hubbert - yes, and for my trades at £150K, I factor in a 7.5p increase in GSK share price is required for my costs to break even. ..... ;0)
24/6/2016
13:45
tradermichael: With the upward movement of the GSK share price this morning, I'm thinking we should have dumped the EU years ago ..... ;0)
03/12/2015
09:37
guernseymoney: Latest research I can get my hands on: >> Wednesday, November 11, 2015 >> GlaxoSmithKline CEO call take-aways: Pipeline productivity improving, Consumer guidance could be a conservative base camp >> >> GlaxoSmithKline >> (Neutral) >> >> Company Data >> Price (p) 1,366p >> Date of Price 10 Nov 2015 >> >> Yesterday we hosted a call with GSK CEO Andrew Witty (AW) in the context of the J.P. Morgan EU Pharma 2015 CEO Conference Call Series. Coming a week after the R&D day, which was focused on the detailed pipeline project disclosure, the call focused on bigger picture R&D questions, as well as the outlook for GSK's Consumer division and the pace of the cost savings program. On R&D, AW believes GSK has a differentiated approach, in part because of its understanding of genetics. GSK will provide an update on its R&D productivity metric at FY15 results in Feb '16, and AW believes GSK's productivity has been increasing, though still similar to the 12% IRR reported in 2014. With regard to the Consumer division, AW stated that guidance for topline growth of mid-single digit, and Core EBIT margin guidance of 20%+ could ultimately prove conservative, and doesn't represent a ceiling, though achieving profitability beyond 20% could mean a trade-off for slower topline growth. AW suggested significant M&A to strengthen Consumer is unlikely until the Novartis synergies have been achieved, and he also suggested that although divestment of the Consumer division wouldn't make sense at this time, this could be an option by the end of the decade, once the Novartis cost savings / synergies plan has been executed. For the Cost savings program, AW sees savings continuing to build over the next three quarters, suggesting guidance for 2016 EPS growth crossing into double digit should be well underpinned. >> Bottom-line: With the R&D day past, we see limited upcoming clinical catalysts with the potential to drive upgrades, but we believe GSK's share-price will likely be well supported by the sector-leading dividend yield (c.6%), as well as the Q2'16 Special divi (1.5%), and we also believe delivery of double digit LC EPS growth in 2016 would be well received by investors. With GSK already trading on 16x 2016E Core EPS for only 5% 2016E-20E EPS CAGR, vs. the sector on c.16.5x 2016E for 8% EPS CAGR, we remain Neutral. R&D - AW believes GSK's R&D is differentiated by its ability to understand genetics and gene expression. He believes R&D productivity is increasing, and is competitive with peers, >> * Differentiators in the R&D approach. AW notes GSK's ability to understand the genetics of diseases it is studying. He believes it has a leadership position in epigenetics, pattern recognition, RIP kinases, IL-5 in immune-system modulation and respiratory. He also believes it has a competitive position in immuno- oncology. In terms of platforms, the company sees differentiation in having adjuvants and adeno-virus technology within vaccines. * R&D productivity is improving vs. historical trends. GSK sees improvements as it believes it is doing a better job in validating its targets earlier in development, and choosing better target at the molecular level, which should lead to a higher probability of success vs. historical trends. * GSK's Return on R&D (IRR) is competitive, and likely to be similar to the 12% reported in 2013. GSK calculates its Internal Rate of Return every two years, with the next update at FY15 results in Feb 2016. GSK expects the IRR to be similar to the 12% reported in 2014. This was a step-up from themed single digit return reported in 2007/08. GSK expects the return to have increased, as HIV launches have done better, more than offsetting slow respiratory launches. GSK also believes that ending the Darapladib and Losmapimod programs will have increased the returns, as the studies ended, reducing R&D cost. GSK also sees oncology divestment at an attractive price as having boosted the return. * R&D productivity can be measured in a number of ways, all of which look favourable. AW listed a number of different ways to measure R&D productivity, including measuring spend per NDA approval, or looking at cycle times to approval - on both of these, GSK looks very good. Another metric would be the number of approvals generated, which GSK believes looks very good. GSK concedes one metric where it could look less impressive than peers is the number of blockbusters being generated from its pipeline, but it notes that 2008-14 combined new launches were already generating £3bn annual sales by the end of 2014, a significant commercial return. GSK also notes recent progress, with Dolutegravir looking likely to be a very substantial product, with peak sales of Breo, Nucala and Shingrix also likely to be very significant. GSK still sees plenty of potential to drive up its average R&D yield. Of the 11 pipeline products >> (9 launched and Nucala just approved and Shingrix to file H2' 2016), GSK believes 3-5 could be very significant products. * GSK R&D productivity doesn't significantly differ by therapy area. GSK doesn't see Oncology as having lower R&D productivity than other therapy areas, as it has had 7 oncology NDAs approved in Oncology from 2008-13, with sales moving from zero to £1bn by time of Oncology divestment. Respiratory is a therapy area GSK is still very keen on, with lots of activity and high productivity. >> GSK also characterised HIV as having been very productive. Vaccines also has very good productivity. GSK was slightly more cautious on Immuno- inflammation, a newer therapy area for GSK, which is a noisy space that could potentially have lower productivity. Rare disease productivity was described as good, rather than very good. * R&D focus - GSK is focused on six therapy areas: (1) HIV/Infection, (2) Oncology, (3) Respiratory, (4) Immuno-Inflammation, (5) Rare disease and (6) Vaccines. Though GSK has 40 new medicines/vaccines in developments, GSK doesn't believe it is too broadly spread across therapy areas, and the company doesn't see an argument for narrowing the R&D focus. * R&D approach seeks to avoid >> cannibalisation: In the Respiratory category, GSK does see a finite opportunity to develop new inhaled therapies, hence this is less of a focus, with GSK instead focusing on immune modulated programs like IL5 instead, which won't cannibalise existing GSK products, or compete with generics. In HIV, GSK still sees opportunity for long acting therapy, or from combos using a fewer number of ingredients which could expand the franchise rather than cannibalising. In the categories of Immuno-oncology, Inflammation or Rare diseases, GSK has nothing to lose, so can go after everyone else's share. >> Consumer: topline and margin guidance could ultimately prove conservative, and doesn't represent a ceiling, though achieving profitability beyond 20% could mean a trade-off for topline growth * Consumer topline and margin guidance could ultimately prove conservative. As to whether the guidance for mid single digit topline growth and 20%+ margin by 2020 could be conservative, AW noted that the Novartis business GSK acquired had significant challenges in terms of starting profitability. The company aspires to take the combined business to the upper quartile on margin and topline growth rate. GSK notes the profitability guidance is for EBIT margins to be at "least 20%", not "20%". AW sees reaching 20% profitability as the base-camp GSK needs to initially reach, before potentially exceeding this. The company notes that at some profitability point beyond 20% margin, there could be a topline growth trade-off, though this does not necessarily start at 20%. To put the profitability guidance in context, GSK noted that its Indian business has a significantly lower margin. In terms of peers, it also suggested J&J's consumer business is closer to GSK's, with this business having a sub 20% margin. GSK believes Reckitt is a less relevant comparator on profitability (JPMe approaching >> 30%) and GSK notes Reckitt hasn't formally provided any profitability metrics for its comparable business. * Consumer growth likely to be organic-only, until GSK has fully executed on Novartis transaction. GSK ruled out any potential near-term bolt on deals for GSK's consumer division, as the focus remains on executing on Novartis integration and margin improvement. GSK doesn't see the Novartis Put option creating any additional pressure to speed up the pace of margin improvement, with this already being a focus for GSK. Once the integration is complete and GSK has reached "base-camp" it would consider Consumer bolt-on M&A. >> * Consumer could potentially be spun-off once the Novartis transaction has been fully executed in 2020, but not before. GSK doesn't see an argument for divesting Consumer at the current time, seeing significant synergies with Pharma, and seeing plenty of potential for the business to be optimised. Once this is achieved, with Novartis Consumer fully integrated and the margin aspiration achieved by the end of the decade, at this time GSK could consider whether it makes sense to break the business up. Cost >> savings: AW sees significant further cost savings continuing to build over the next three quarters. * Cost savings will continue to play out in the next three quarters. AW stated that the initial cost savings apparent in >> Q3'15 would continue to build in the next three quarters, as restructuring measures fully materialise. However GSK believes a significant proportion of the savings will be offset by EU Advair erosion, and pricing headwinds. >> We believe 2016 could savings should support GSK's 2016 guidance for EPS growth to cross into double digit. >> Key newsflow >> * Key 12m newsflow: GSK highlighted a number of significant upcoming datapoints, including: (1) Nucala launch, (2) Accelerating Breo/Anoro/Incruse roll-out, (3) Shingrix regulatory filing, (4) Cabotegravir Phase III start, (5) HIF Phase III start, (6) First approval of SCID gene therapy. >> Investment Thesis >> We rate GSK Neutral, as we see balanced risk/reward at current levels. We see consensus EPS forecasts for the next five years as being broadly achievable, and we expect the sector-leading dividend yield to provide a valuation floor, at least as long as the high payout ratio is maintained. >> We are Neutral rather than Overweight as we continue to see limited pipeline optionality and less M&A optionality than at peers due to GSK's high financial leverage. >> Valuation >> We set a £13.70 price target applying a sector multiple to GSK's 2016E Core EPS. The sector currently trades on c.16x 2016E PE, for 9% 2016E-20E EPS CAGR. We apply a 16x multiple to GSK Core EPS, fairly generous for only a 6% 2016E-20E EPS CAGR, acknowledging that, in the near term, the shares are likely to be supported by the sector-leading dividend yield, even if we do question the logic of maintaining such a high payout ratio (96% of Core EPS, 200% of FCF). >> Our £13.70 PT is in line with our £13.50 Embedded value and £13.60 SOP. >> Risks to Rating and Price Target >> Upside risks >> * GSK could buy out Pfizer's 12% ViiV stake, though we would see this driving only around 1% accretion for 2016 and 2017, with 2% accretion beyond. >> Downside risks >> * GSK's dividend provides valuation support, but this could be at risk, should the company undertake a strategic transaction
13/11/2015
11:49
minerve: RCTurner2 No. I believe yesterday's (and previous days) news and events indirectly affected the sentiment and actions on GSK's share price Take this hypothesis further, if metal prices and oil prices continued towards zero do you think this would have no further affect on the GSK share price because you believe it as just 'noise'?
28/8/2015
23:15
cyberian: After hours close(Friday) on WS the GSK share price was equiv. £13.43!!!
17/2/2015
17:05
losos: Toffeeman - "market makers have jack sh1t to do with the GSK share price." Yes, you're right, but they do move the aim and small cap spreads around to suit themselves, had been watching their antics on XPP and a few others.
12/2/2015
14:31
cyberian: The present share price seems odd when you look at the forward divi guidance and the net Novartis return value to shareholders as that gives a 10.8% return over the next 12 months. Plus we have some clear guidance from the Board that the pipe-line is looking very encouraging, with respiratory products having something of a significant recovery/improvement, plus the appointment of 3 major banks mandated to examine the possible float of their HIV products (maybe worth $15/18 billion). Further there is the latest news that with other major sector names they are looking at initiating a single process of blending components of certain drugs which would save up to 50% of processing costs (they have a plant nearly ready in Singapore for this purpose)...obvious some savings can and probably be shared to the wholesale buyers, but net margin returns will benefit GSK. The latter have already announced that they are introducing further cost saving factors in the US. Again as stated by others and some credible analysts the GSK share price is presently at a 20% discount to its main peers....so just need to be patient, I guess.
01/8/2014
08:48
rangor: "The fall in the GlaxoSmithKline (GSK) share price to1428p is a story in its self. Not only is it back to where it approximately was in 2013 but it now stands on what I perceive to be a three year support level. (Have a look for yourselves.) If so, will the share price hold there and is it a reason to buy the shares as cheap at 1428p on an historic dividend yield of 5.4% and on the basis that "there will always be a Glaxo"; an approach that has generally speaking been a good point to buy the shares when the news looks bleakest?" Except that in 2012 GSK share price went as low as 1317, and in 2011 spent half the year below £13.
GlaxoSmithKline share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20170824 10:35:52